683 Capital Management’s Orchestra BioMed OBIO Stock Holding History

683 Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-185,000	Closed	-$786K	–	210
2026 Q1	$786K	Sell	185,000 -19,076	-9%	-$81.2K	0.04%	151
2025 Q4	$847K	Buy	+204,076	New	+$823K	0.04%	158
2022 Q3	–	Sell	-10,000	Closed	-$100K	–	247
2022 Q2	$100K	Hold	10,000	–	–	0.01%	189
2022 Q1	$99K	Hold	10,000	–	–	0.01%	289
2021 Q4	$101K	Hold	10,000	–	–	﹤0.01%	303
2021 Q3	$99K	Hold	10,000	–	–	﹤0.01%	193
2021 Q2	$102K	Hold	10,000	–	–	﹤0.01%	189
2021 Q1	$112K	Hold	10,000	–	–	0.01%	156
2020 Q4	$128K	Hold	10,000	–	–	0.01%	203
2020 Q3	$110K	Buy	+10,000	New	+$112K	0.01%	132

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

683 Capital Management's OBIO Position: Q2 2026 in Review

683 Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 185,000 shares — an estimated $786K sold.

683 Capital Management first reported a position in OBIO in Q3 2020 and held it in 10 quarters. The position peaked at $847K in Q4 2025. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

683 Capital Management reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 185,000 Orchestra BioMed shares in Q2 2026, an estimated $786K.
683 Capital Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 10 quarters.
683 Capital Management's Orchestra BioMed position peaked at $847K in Q4 2025.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.